Continuing Equivalence: Is There an End to the Story?
Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector · 2008
DOI: 10.1057/jgm.2008.19 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector, 2008. Verfasst von Roger L. Williams und 1 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
For many active pharmaceutical ingredients and their corresponding drug products, the possibility of a single global system of harmonised bioequivalence and pharmaceutical equivalence requirements for first-entry and interchangeable multi-source drug products may be considered. The topic should be of interest to all manufacturers, to practitioners and patients as well, and to government policy-makers. In an era when substandard, counterfeit, and adulterated medicines are increasingly available, the topic requires careful consideration.
Zitieren
APA
Williams, R. L., & Shah, V. P. (2008). Continuing Equivalence: Is There an End to the Story?. Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector. https://doi.org/10.1057/jgm.2008.19
Vancouver
Williams RL, Shah VP. Continuing Equivalence: Is There an End to the Story?. Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector. 2008. doi:10.1057/jgm.2008.19
BibTeX
@article{Williams2008,
author = {Williams, Roger L. and Shah, Vinod P.},
title = {Continuing Equivalence: Is There an End to the Story?},
journal = {Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector},
year = {2008},
doi = {10.1057/jgm.2008.19}
}
EUVIMED